Iktos, Merck collaborate on AI for new drug designs

By The Science Advisory Board staff writers

November 5, 2020 -- Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.

The partnership will allow Merck to use Iktos' generative design technology to develop a drug discovery program. Iktos' software creates virtual novel molecules for treating particular diseases. The company markets its AI technology as both services and software, it said; its AI software as a service (SaaS) software is called Makya and its AI SaaS platform, Spaya.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.